BRCA2 reversion mutation confers resistance to olaparib in breast cancer.
Yamamoto S, Kawashima K, Fujiwara Y, Adachi S, Narui K, Hosaka C, Takahashi R, Tsuyuki S, Sugimori M, Tanoshima M, Sasamoto M, Oshi M, Yamada A, Kunisaki C, Endo I.
Yamamoto S, et al. Among authors: tanoshima m.
Clin Case Rep. 2023 Jun 23;11(6):e7537. doi: 10.1002/ccr3.7537. eCollection 2023 Jun.
Clin Case Rep. 2023.
PMID: 37361653
Free PMC article.